A Vision for the Future: Reducing the Burden of Anti-VEGF Therapy With Emerging Options
Evolving advances for the treatment of neovascular retinal diseases have the potential to further enhance visual acuity outcomes while reducing treatment burden. Several novel delivery systems, along with therapies that target alternate pathways, are currently being evaluated in clinical studies. Understanding these therapeutic advances prior to their possible approval is imperative for their optimal integration into clinical practice. In this educational activity, experts in the field review the burden associated with current treatment strategies in neovascular retinal diseases, investigate the role of subretinal fluid in determining response to treatment, as well as evaluate new and emerging modalities that may reduce the burden of anti-vascular endothelial growth factor (VEGF) therapy in neovascular retinal diseases.
Cost: FreeView Offer chevron_right
Free; 0.75 AMA PRA Category 1 Credit(s)™; The My Healio CME Dashboard keeps track of earned credits and saved activities; Personalized recommendations make finding your next activity easy; Over 50,000 of your colleagues know that earn credits is faster and easier with Healio CME
Neovascular retinal disease; Subretinal fluid; Anti-vascular edothelial growth factor; anti-VEGF
Upon successful completion of this activity, participants should be better able to: -Review the burden associated with current therapies used for the treatment of neovascular retinal diseases. -Investigate the role of subretinal fluid in determining response to treatment in neovascular retinal diseases. -Evaluate new and emerging modalities that may reduce the burden of anti-VEGF therapy in neovascular retinal diseases.
The intended audience for this acitivty is ophthalmologists, retina specialists, and other health care professionals involved in the management of patients with neovascular retinal diseases.
Additional credit info
Provider Statement This continuing medical education activity is provided by Vindico Medical Education. Support Statement This educational activity is supported by an educational grant from GlaxoSmithKline. Accreditation This activity is supported by an educational grant from Genentech, Inc. Credit Designation Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Ophthalmology’s Maintenance of Certification (ABO MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting MOC credit. Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn MOC credits equivalent to the amount of CME credits claimed for the activity. The CME activity provider will submit learner completion information to the ACCME for the purpose of granting ABO MOC credits within 30 days of activity completion. This enduring material is approved for 1 year from the date of original release, October 30, 2020, through October 29, 2021.